3100 Woodcreek Drive
Downers Grove, IL 60515-5400
Phone: 630-271-7000

John Bishop, president and CEO
Wholly owned subsidiary of Abbott Laboratories


Incorporated in 1991, Vysis is a genomic disease management company that develops, commercializes and markets clinical products providing information for the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis has European operations in Germany, the United Kingdom and France and international distribution in Fujisawa, Japan, and 51 other countries.

Fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) serve as the company’s technology base. The company markets three products: PathVysion HER-2 DNA Probe kit, used to detect breast cancer and also under FDA consideration as a means to select patients for Herceptin therapy; the Vysis UroVysion Bladder Cancer Recurrence kit; and The AneuVysion Assay, used to detect certain fetal defects.

Vysis owns or has an exclusive license to 119 issued U.S. patents or allowed U.S. patent applications and 56 pending U.S. patent applications in the areas of genetic and infectious disease testing.

In December 2001, Abbott Laboratories completed its acquisition of Vysis in a $355 million cash deal.


Vysis has research collaborations with the University of California, San Francisco; the Mayo Clinic; the University of Chicago; the Reproductive Genetics Institute and the Public Health Research Institute of New York, among others. Also, it maintains collaborations with Incyte Genomics Inc. and Digital Scientific Ltd., as well as Genentech Inc. and Hoffmann-La Roche Inc.